Eui Hyun Kim1, Min Chul Oh2, Jong Hee Chang3, Ju Hyung Moon1, Cheol Ryong Ku4, Won-Seok Chang5, Eun Jig Lee6, Sun Ho Kim7. 1. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Pituitary Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. 2. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Pituitary Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Pituitary Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Gamma Knife Center, Yonsei University College of Medicine, Seoul, Republic of Korea. 4. Pituitary Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Endocrinology, Yonsei University College of Medicine, Seoul, Republic of Korea. 5. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Gamma Knife Center, Yonsei University College of Medicine, Seoul, Republic of Korea. 6. Pituitary Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Endocrinology, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Endocrinology Department of Endocrinology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 7. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Pituitary Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: sunkim@yuhs.ac.
Abstract
OBJECTIVE: We aimed to determine the long-term effects of Gamma knife radiosurgery (GKS) on remnants in the cavernous sinus (CS) after transsphenoidal surgery (TSS) for acromegaly and to identify its possible adverse effects. METHODS: Thirty patients who had remnant tumors only inside the CS after TSS and who consequently underwent GKS were included. They were followed for a median period of 47 months after GKS with regular hormonal and radiologic examinations. RESULTS: The mean tumor volume and margin dose irradiated by GKS was 3.7 cm3 and 26.2 Gy, respectively. Radiologic tumor control was identified in all patients, and no tumor regrowth or recurrent tumors were identified. For 14 patients who achieved endocrinologic remission, the median duration from GKS until remission was 35 months. The actuarial rates of remission at 2, 5, and 10 years were 7.1%, 43.6%, and 65.6%, respectively. The degree of decrease in the nadir GH level in the OGTT at 6 months after GKS was a statistically significant predictor of remission. Newly developed hypopituitarism frequently developed in a time-dependent manner. Radiation necrosis developed in 4 patients with relatively large remnant volumes. CONCLUSIONS: GKS is an effective adjuvant treatment option for remnant tumors inside the CS after TSS. Maximal surgical resection, leaving minimal volume of remnants only inside the CS, allows the safe and sufficient delivery of a radiation dose to tumors, thereby increasing the possibility of remission. However, the risk of new hypopituitarism and radiation necrosis should be considered when tumors inside the CS are treated with GKS.
OBJECTIVE: We aimed to determine the long-term effects of Gamma knife radiosurgery (GKS) on remnants in the cavernous sinus (CS) after transsphenoidal surgery (TSS) for acromegaly and to identify its possible adverse effects. METHODS: Thirty patients who had remnant tumors only inside the CS after TSS and who consequently underwent GKS were included. They were followed for a median period of 47 months after GKS with regular hormonal and radiologic examinations. RESULTS: The mean tumor volume and margin dose irradiated by GKS was 3.7 cm3 and 26.2 Gy, respectively. Radiologic tumor control was identified in all patients, and no tumor regrowth or recurrent tumors were identified. For 14 patients who achieved endocrinologic remission, the median duration from GKS until remission was 35 months. The actuarial rates of remission at 2, 5, and 10 years were 7.1%, 43.6%, and 65.6%, respectively. The degree of decrease in the nadir GH level in the OGTT at 6 months after GKS was a statistically significant predictor of remission. Newly developed hypopituitarism frequently developed in a time-dependent manner. Radiation necrosis developed in 4 patients with relatively large remnant volumes. CONCLUSIONS: GKS is an effective adjuvant treatment option for remnant tumors inside the CS after TSS. Maximal surgical resection, leaving minimal volume of remnants only inside the CS, allows the safe and sufficient delivery of a radiation dose to tumors, thereby increasing the possibility of remission. However, the risk of new hypopituitarism and radiation necrosis should be considered when tumors inside the CS are treated with GKS.
Authors: Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli Journal: Endocrine Date: 2020-02-14 Impact factor: 3.633
Authors: Renato Cozzi; Maria R Ambrosio; Roberto Attanasio; Alessandro Bozzao; Laura De Marinis; Ernesto De Menis; Edoardo Guastamacchia; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Pietro Maffei; Maurizio Poggi; Vincenzo Toscano; Michele Zini; Philippe Chanson; Laurence Katznelson Journal: Endocr Metab Immune Disord Drug Targets Date: 2020 Impact factor: 2.895
Authors: Felix Ehret; Markus Kufeld; Christoph Fürweger; Alfred Haidenberger; Paul Windisch; Susanne Fichte; Ralph Lehrke; Carolin Senger; David Kaul; Daniel Rueß; Maximilian Ruge; Christian Schichor; Jörg-Christian Tonn; Günter Stalla; Alexander Muacevic Journal: Cancers (Basel) Date: 2021-01-31 Impact factor: 6.639